We conducted an interventional, experimental, randomized, prospective study to compare the efficacy of a newer therapeutic agent Centchroman with established therapeutic agents Tamoxifen in the treatment of mastalgia and fibroadenoma. Total 84 patients have been participated in the study (only mastalgia–36, mastalgia with fibroadenoma–48). In mastalgia group 19 and 17 patients were treated with Centchroman and Tamoxifen respectively. In fibroadenoma group 26 and 22 patients received Centchroman and Tamoxifen respectively. Centchroman was found to be the most effective drug with the post intervention pain scores =<2 in 30 (66.67%) patients and 17 (43.59%) with Tamoxifen. In fibroadenoma group complete response rate was highest in Centchroman arm 12(26.67%) in comparison to 2(5.13%). Side effects are maximum with Tamoxifen and Centchroman is the cheapest.